When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BMY - FDA Ad Com set for Bristol-Myers' luspatercept for MDS
Bristol-Myers Squibb Company
The FDA's Oncologic Drugs Advisory Committee will meet on Wednesday, December 18, to review and discuss Bristol-Myers Squibb's (BMY-0.4%) supplemental marketing application seeking approval to use Reblozyl (luspatercept-aamt) to treat patients myelodysplastic syndromes (MDS), specifically those with very low-to-intermediate-risk MDS-associated anemia who have ring sideroblasts and require red blood cell transfusions.
More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Healthcare stocks news,